학술논문
Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years – updated evidence from Indian follow-up cohort study
Document Type
article
Author
Partha Basu; Richard Muwonge; Neerja Bhatla; Bhagwan M. Nene; Smita Joshi; Pulikottil O. Esmy; Usha Rani Reddy Poli; Geeta Joshi; Yogesh Verma; Eric Zomawia; Surendra S. Shastri; Sharmila Pimple; Devasena Anantharaman; Priya R. Prabhu; Sanjay Hingmire; Catherine Sauvaget; Eric Lucas; Michael Pawlita; Tarik Gheit; Kasturi Jayant; Sylla G. Malvi; Maqsood Siddiqi; Angelika Michel; Julia Butt; Subha Sankaran; Thiraviam Pillai Rameshwari Ammal Kannan; Rintu Varghese; Uma Divate; Martina Willhauck-Fleckenstein; Tim Waterboer; Martin Müller; Peter Sehr; Shachi Vashist; Gauravi Mishra; Radhika Jadhav; Ranjit Thorat; Massimo Tommasino; M. Radhakrishna Pillai; Rengaswamy Sankaranarayanan
Source
Papillomavirus Research, Vol 7, Iss , Pp 75-81 (2019)
Subject
Language
English
ISSN
2405-8521
Abstract
Earlier publication from the ongoing multi-centric study of the International Agency for Research on Cancer to evaluate less than three doses of the quadrivalent Human Papillomavirus (HPV) vaccine in India amongst unmarried girls demonstrated non-inferior total antibody titres, neutralizing antibody titres and antibody avidity in 2-dose recipients compared to 3-dose recipients at 15–18 years of age (Bhatla et al., 2018) [7].The number of participants recruited at 15–18 years of age was 1515 and 1795 in the 3-dose and the 2-dose groups respectively. At a median follow-up of 7 years, incident HPV 16/18 infections were detected in 1.6% women receiving two doses and 0.8% women receiving three doses at 15–18 years. Frequency of incident infection was 7.0% in the age- and site-matched unvaccinated women (N = 1484). No persistent infection from HPV 16 was observed in the 2- or 3-dose recipients and one (0.2%) persistent HPV 18 infection was documented, each in the 3-dose and 2-dose cohorts. Among the unvaccinated women, the frequency of HPV 16/18 persistent infection was 1.7%.The protection offered by two doses of quadrivalent HPV vaccine against incident and persistent infections in recipients at 15–18 years is comparable to that seen in 3-dose recipients at 15–18 years. Keywords: Human papillomavirus, Quadrivalent vaccine, Two doses, Age 15–18 years, Immunogenicity, Incident infections, Persistent infections